Confirmed Speakers

•  Derek Abbott, Ph.D., Director, Analytics, Amyris, Inc. 
•  Sreedhara Alavattam, Ph.D., Principal Scientist and Senior Group Leader, Genentech, Inc.
•  Alina Alexeenko, Ph.D., Professor, School of Aeronautics and Astronautics, Purdue University 
•  Afreen Allam, MBA, CEO & President, SiNON Therapeutics 
•  Arun Alphonse Ignatius, Ph.D., Principal Scientist, Pfizer 
•  Richard Altman, MS, Scientist, Protein Technologies, Amgen 
•  Philip An, Scientist, Biologics, Amgen 
•  Mark Arbing, Ph.D., Core Facility Director, UCLA-DOE Institute, University of California, Los Angeles
•  Frederick Arce-Vargas, M.D., Ph.D., Research Associate, University College London Cancer Institute, United Kingdom 
•  Juan Aon, Ph.D., Senior Manager, MCCD, RD Biopharm, R&D, GSK 
•  Paul Armistead, M.D., Ph.D., Associate Professor, Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 
•  Tasneem Bahrainwala, PhD, Analytical Sciences Mass Spectrometry Group Leader, MacroGenics, Inc. 
•  Yun Bai, Ph.D., Director, Ambrx, Inc. 
•  Ramesh Baliga, Ph.D., Vice President, Discovery Biology, IGM Biosciences 
•  Sashikanth Banappagari, Ph.D., Scientist II, Formulation Development, Vaccine Production Program/VRC/NIAID/NIH 
•  Scott Banta, Ph.D., Professor, Chemical Engineering, Columbia University 
•  Yoram Barak, Ph.D., Biosciences Innovation Manager, BASF Enzymes, LLC 
•  Nicola Beaucamp, Ph.D., Head, Process Research, Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH 
•  Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton, United Kingdom 
•  Robert D. Bell, Ph.D., Senior Principal Scientist, Neurovascular Biology Lab Head, Pfizer, Inc. 
•  Frank Bernhard, Ph.D., Lab Leader, Institute of Biophysical Chemistry, Goethe University Frankfurt 
•  Akhilesh Bhambhani, Ph.D., Principal Scientist & Group Leader, New Technologies-Vaccine Drug Product Development, Merck & Co., Inc. 
•  David Bienvenue, Senior Director, Protein Sciences, Aptevo Therapeutics 
•  Uli Binder, Ph.D., CTO, XL-Protein 
•  Joerg Birkenfeld, Ph.D., Section Head, High Throughput Biologics, R&D Biologics Research/Protein Therapeutics, Sanofi-Aventis Deutschland GmbH 
•  Eric Bishop, MBA, MSc, Vice President, Research & Development, Cygnus Technologies
•  Ruben Boado, Ph.D., Vice President, Research & Development/Co-Founder, ArmaGen, Inc. 
•  Christopher Boddy, Ph.D., Professor & Director, Biochemistry Program, University of Ottawa 
•  Berthold Boedeker, Ph.D., Chief Scientist, Global Biologics Development, Bayer Pharma AG 
•  Jonathan Bones, Ph.D., Principal Investigator, Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training 
•  Katherine Bowers, Ph.D., Principal Scientist, Group Leader, Analytical and Formulation Development, FUJIFILM Diosynth Biotechnologies
•  Andrew Bradbury, Ph.D., CSCO, Specifica, Inc.
•  David Bramhill, Ph.D., Founder, Bramhill Biological Consulting, LLC 
•  Christoph Brandenbusch, Ph.D., Group Leader, Biochemical and Chemical Engineering, Technical University, Dortmund, Germany 
•  Juma Bridgewater, Ph.D., Senior Scientist, Analytical Sciences and Technology, Bristol-Myers Squibb 
•  Ulrich Brinkmann, Ph.D., Expert Scientist, Scientific Director, Roche Pharma Research & Early Development, Roche Innovation Center Munich 
•  John Burke, Ph.D., Co-Founder, President, CEO, Applied BioMath, LLC
•  Marco Cacciuttolo, Ph.D., Head of Operations, Batavia Biosciences
•  William Callahan, Senior Scientist, Amgen 
•  Julio A. Camarero, Ph.D., Professor, Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California 
•  Marie Caparon, Ph.D., Associate Research Fellow, Bioprocess R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc.
•  Paul J. Carter, Ph.D., Staff Scientist and Senior Director, Antibody Engineering, Genentech, Inc. 
•  Mauro Castellarin, Ph.D., Postdoctoral Researcher, Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine 
•  Steven Chamow, Ph.D., Principal Consultant, Chamow & Associates, Inc. 
•  Wei-Chiang Chen, Ph.D., Scientist, Analytical Development, Biogen
•  Zhilei Chen, Ph.D., Associate Professor, Microbial Pathogenesis and Immunology, Texas A&M College of Medicine 
•  David Chiu, Ph.D., Scientist, Analytical Sciences, Seattle Genetics 
•  Yongku Cho, Ph.D., Assistant Professor, Chemical and Biomolecular Engineering, University of Connecticut 
•  Partha Chowdhury, Ph.D., Senior Director and Head, Antibody Discovery, Sanofi Genzyme 
•  Marcus T. Cicerone, Ph.D., Biomaterials Group, National Institute of Standards and Technology 
•  Jeannick Cizeau, Ph.D., Director, Research, Eleven Biotherapeutics, Inc. 
•  Bernardo Cordovez, Ph.D., President, Halo Labs 
•  Tsafi Danieli, Ph.D., Director, BioGiv Excubator & Head, Protein Expression Facility, Wolfson Centre for Applied Structural Biology, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem  
•  Gregory Daniels, M.D., Ph.D., Professor, Medicine, Moores Cancer Center, University of California, San Diego 
•  Rebecca Davis-Harrison, Ph.D., Research Scientist, BioTechnology Discovery Research, Eli Lilly and Company 
•  Kangwen Deng, Ph.D., Senior Scientist, Biologics, AbbVie 
•  Mehabaw G. Derebe, Ph.D., Scientist, Biologics Engineering, Janssen BioTherapeutics 
•  Jason DeVoss, Ph.D., Senior Scientist, Oncology, Amgen 
•  Iskandar Dib, Ph.D., Principal Scientist DSP & Analytics, VTU Technology GmbH
•  Craig D. Dickinson, Ph.D., Senior Research Advisor, AME, Eli Lilly and Company 
•  Gundo Diedrich, Ph.D., Associate Director, Antibody Engineering, MacroGenics, Inc. 
•  Dimiter S. Dimitrov, Ph.D., Senior Investigator, Protein Interactions Section, Cancer and Inflammation Program, National Cancer Institute, NIH 
•  Rakesh Dixit, Ph.D., DABT, Vice President, R&D, MedImmune/AstraZeneca 
•  Robert Dream, Ph.D., Managing Director, HDR Company LLC 
•  André C. Dumetz, Ph.D., Senior Scientific Investigator, Biopharm Downstream PD-3, R&D Platform Technology & Science, GlaxoSmithKline 
•  Jiali Du, Ph.D., Scientist, Formulation Sciences, MedImmune 
•  Mike Dyson, Ph.D., CTO, IONTAS, Ltd. 
•  Mark Ellis, Principal Scientist, Protein Expression and Purification, UCB Pharma 
•  Sam Ellis, Vice President, Thomson Instrument Company 
•  Adam Feist, Ph.D., Project Scientist, Systems Biology Research Group, University of California 
•  Timothy Fenn, Ph.D., Principal Scientist, Boehringer Ingelheim 
•  Vasco Filipe, Ph.D., Lab Head, Pharmaceutical Development Biologics, Sanofi 
•  Nicolas Fischer, Ph.D., Head, Research, Novimmune SA, Switzerland 
•  Heather Flores, BS, Scientist, Technical Development Scientist, Late Stage Pharmaceutical Development, Genentech, Inc. 
•  Søren Flygenring Basset, Ph.D., Director, R&D, Novo Nordisk Pharmatech A/S 
•  Björn Frendéus, Ph.D., CSO, Bioinvent, Sweden 
•  Timo Frensing, Ph.D., Senior Scientist, Cell Culture Research, Roche Diagnostics GmbH  
•  Per-Ola Freskgard, Ph.D., Vice Director and Senior Leader, Neuroscience, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. 
•  Douglas Fuerst, Ph.D., Director, GSK Fellow, Advanced Manufacturing Technologies, GlaxoSmithKline 
•  Peter Fung, Ph.D., Senior Manager, Product Marketing, NanoTemper Technologies
•  Julia Gavrilyuk, Ph.D., Principal Research Scientist, Chemistry Lead, Discovery Chemistry, Abbvie StemcentRx, Inc. 
•  Paul Gianella, Ph.D., Postdoctoral Research Fellow, Amgen, Inc.
•  Henning Gieseler, Ph.D., CSO, Pharmaceutical Development, GILYOS GmbH 
•  Ryan T. Gill, Ph.D., Slade Professor, Chemical and Biological Engineering, University of Colorado 
•  Pierre-Alain Girod, CSO, Selexis 
•  Adam Goldstein, MSc, Principal Scientist, Global Technology, Roche/Genentech 
•  Christoph Goletz, Associate Director, Immunomodulation, Glycotope GmbH 
•  Christopher H. Gray, Ph.D., Team Leader, Structural Biology, Drug Discovery Program, CRUK Beatson Institute 
•  Karl E. Griswold, Ph.D., Associate Professor, Thayer School of Engineering, Dartmouth College 
•  Flaviu Gruia, Ph.D., Principal Scientist, Drug Product Analytical Development, Moderna Therapeutics 
•  Jijie Gu, Ph.D., Research Fellow and Function Head, Immunology Discovery, AbbVie Bioresearch Center 
•  Kapil Gupta, Ph.D., Associate Director, Protein Pharmaceutical Development, Biogen 
•  Claes Gustafsson, CCO & Founder, ATUM (formerly DNA2.0) 
•  Shiang Gwee, Scientist, Drug Product Sciences, MacroGenics, Inc. 
•  Andrew Holloway, Senior Research Associate, Analytical Sciences, Seattle Genetics, Inc. 
•  Amy Han, Ph.D., Director, Chemistry, Regeneron Pharmaceuticals
•  Brian Hall, Ph.D., Principal Scientist, Biologics, Merck & Co. 
•  Christian Harding, Ph.D., CSO, VaxNewMo 
•  Feras Hatahet, Ph.D., Scientist, Protein Technologies, Amgen 
•  Cheng Her, Ph.D., Postdoctoral Research Fellow, Carpenter Lab, Pharmaceutical Sciences, University of Colorado-Denver, Anschutz Medical Campus 
•  Robert Herbst, Ph.D., Director, Process Development and Engineering, ImmunoGen, Inc. 
•  Mark Hildebrand, Ph.D., Research Scientist and Director, Marine Biology Research Division, Scripps Institution of Oceanography, University of California, San Diego 
•  Oliver Hill, Ph.D., Vice President, Molecular Biology/Protein Engineering, Apogenix AG 
•  Sophia Hober, Ph.D., Professor, Molecular Biotechnology, KTH Royal Institute of Technology 
•  Bushra Husain, Ph.D., Senior Scientific Researcher, Genentech, Inc.
•  Farren Isaacs, Ph.D., Assistant Professor, Molecular Cellular and Development Biology, Yale University 
•  Jorge Iván Alvarez, Ph.D., Assistant Professor, Department of Pathobiology, University of Pennsylvania 
•  Lavanya Iyer, Ph.D., Research Investigator, Bristol-Myers Squibb
•  Renaud Jacquemart, Ph.D., BioPharma Downstream Process Specialist, Natrix Separations 
• Harsh Jain, Ph.D., Visiting Associate, FDA
•  Jacob Janey, Ph.D., Associate Director, BMS 
•  Miroslaw Janowski, M.D., Ph.D., Associate Professor, Radiology, Johns Hopkins University
•  Donald L. Jarvis, Ph.D., Professor, Molecular Biology, University of Wyoming 
•  Ben Jeyaretnam, E&L Analytical Lead, Sanofi 
•  Haiyan Jiang, Ph.D., Principal Scientist, Biologics Research, Janssen BioTherapeutics, Janssen R&D 
•  Nathan H. Joh, Ph.D., Scientist, Attribute Sciences, Amgen 
•  Matt Johnson, Ph.D., CSO, Avacta Life Sciences
•  Aled Jones, Senior Product and Applications Manager, ProZyme 
•  Sagar Kathuria, Ph.D., Senior Scientist, Protein Engineering, Sanofi Genzyme 
•  John K. Kawooya, Ph.D., Director, Biologics Optimization, Discovery Research, Amgen 
•  Alex Kelly, Business Development Manager, Retrogenix Limited 
•  Eric Kelsic, Ph.D., Staff Scientist, George Church Laboratory, Wyss Institute, Harvard Medical School 
•  Kristin Kemmerich, Ph.D., Head, Antibody Generation Section, National Research Council Canada 
•  Christopher Kemp, Ph.D., President, Kempbio 
•  Sophia Kenrick, Ph.D., Senior Applications Scientist, Wyatt Technology 
•  Tarik Khan, Ph.D., Group Leader, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche Ltd., Switzerland 
•  Maura Kibbey, Ph.D., Director, Global Biologics, U.S. Pharmacopeia 
•  Takanori Kigawa, Ph.D., Team Leader, Quantitative Biology Center, RIKEN 
•  Yoshimi Kikuchi, Ph.D., Executive Professional and Group Manager, Recombinant Protein Research Group, Material Development & Application Labs, Ajinomoto Co., Inc. 
•  Philip M. Kim, Ph.D., Associate Professor, Computational and Integrative Biology, University of Toronto, Canada 
•  Yong-Sung Kim, Ph.D., Professor, Molecular Science and Technology, Ajou University, Korea 
•  Jonathan S. Kingsbury, Ph.D., Principal Scientist, Global Pharmaceutical Development Biologics, Sanofi 
•  Marina Kirkitadze, Ph.D., Deputy Director, Head of Biophysics and Conformation Unit, Analytical R&D Biochemistry, Sanofi Pasteur, Canada 
•  Uday Kishore, Ph.D., Associate Professor, Biosciences, Brunel University London 
•  Georg Klima, Dipl. Ing., Executive Director, Process Science, Boehringer Ingelheim RCV GmbH & Co. KG 
•  Manfred Konrad, Ph.D., Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry 
•  Marie Kosco-Vilbois, Ph.D., CSO, NovImmune SA 
•  Thomas E. Kraft, Ph.D., Postdoctoral Scientist, Large Molecule Research, Roche Diagnostics GmbH 
•  Simon Krah, Ph.D., Senior Scientist, Protein Engineering and Antibody Technologies, Merck KGaA, Germany 
•  Steffen Kreye, Ph.D., Associate Director, USP, Glycotope GmbH  
•  Claus Kristensen, Ph.D., CEO, GlycoDisplay Aps
•  Yoichi Kumada, Ph.D., Associate Professor, Department of Functional Chemistry, Kyoto Institute of Technology 
•  Steven LaBrenz, Ph.D., Scientific Director, Cell and Developability Sciences, PDMS, Janssen R&D 
•  Eilyn R. Lacy, Ph.D., Principal Scientist, Janssen BioTherapeutics (JBIO), Janssen Research & Development, LLC 
•  James Lalonde, Ph.D., Senior Vice President, R&D, Codexis 
•  Lois A. Lampson, Ph.D., Emeritus Associate Professor of Neurosurgery, Brigham & Women’s Hospital/Harvard Medical School 
•  Olga S. Latinovic, Ph.D., Assistant Professor and Head, Lab for Imaging Studies of Pathogens & Cell Interactions and IHV Imaging Facility, Institute of Human Virology and Microbiology and Immunology, University of Maryland  School of Medicine 
•  Thomas Laue, Ph.D., Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire 
•  Gyun Min Lee, Ph.D., Professor, Biological Sciences, KAIST 
•  Jonas Lee, Ph.D., Scientist, Amgen 
•  Toni Lee, Ph.D., Senior Scientist, Biocatalysis, Provivi 
•  Ming Lei, Ph.D., Associate Scientist, Protein Analytical Chemistry, Genentech 
•  Kin-Mei Leung, Ph.D., Principal Scientist, Drug Discovery, F-star Biotechnology, Ltd. 
•  Nathan E. Lewis, Ph.D., Assistant Professor, Department of Pediatrics, University of California, San Diego 
•  Kim Li, Ph.D., DABT, MPH, Senior Manager, Environment, Health, Safety and Sustainability Product Stewardship Toxicology, Amgen 
•  John Löfblom, Ph.D., Associate Professor, Protein Technology, Biotechnology, KTH Royal Institute of Technology 
•  Urs Lohrig, Ph.D., Labhead, Phys. Chem. Characterization, Biosimilars, Biologics Technical Development & Manufacturing, Sandoz GmbH 
•  Thorsten Lorenz, Ph.D., Global Head, Developability Assessment, Integrated Biologics Profiling, Novartis Pharma AG 
•  Nikolai Lorenzen, Ph.D., Large Protein Biophysics, Novo Nordisk A/S 
•  Xiaofeng Lu, Ph.D., Principal Research Scientist, Pharmaceutical Development, AbbVie, Inc. 
•  Haibin Luo, Ph.D., Scientist II, MedImmune LLC 
•  Jacob Luoma, Engineer II, Pharmaceutical Processing and Technology Development, Genentech 
•  Stefan Lutz, Ph.D., Professor and Department Chair, Department of Chemistry, Emory University
•  Haripada Maity, Ph.D., Research Advisor, Formulation Development, CMC Development, Eli Lilly and Company 
•  Anne Marcil, Team Lead, Monoclonal Antibodies, National Research Council, Canada 
•  Thomas Martens, Principal Scientist, Unchained Labs
•  Allan Matte, Ph.D., Senior Research Officer, Downstream Processing & Analytics, Human Health Therapeutics, National Research Council Canada (NRC-CNRC) 
•  Kevin Mattison, Principal Scientist, Bioscience, Malvern PANalytical 
• John McCafferty, Ph.D., CEO, Antibody Engineering, IONTAS, Ltd. 
• Karen McDonald, Ph.D., Professor, Chemical Engineering, University of California, Davis 
• Matthew McGann, Field Applications Manager, Biosciences, Malvern PANalytical
• Colin Medley, Ph.D., Senior Scientist, Small Molecule Pharmaceutical Sciences, Genentech, Inc.
• Torben Moos, M.D., Ph.D., DMSc, Professor, Medicine and Health Technology, Aalborg University 
•  Charles Moore, Ph.D., Research Investigator, Novartis  
•  Phil Morton, Ph.D., Science Director, Bioprocess Characterisation, Albumedix 
•  Thomas Müller-Späth, Ph.D., Senior Scientist, Institute for Chemical and Bioengineering, ETH Zürich 
•  Eric J. Munson, Ph.D., Patrick DeLuca Endowed Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky 
•  Nikhil Ramsubramaniam, Ph.D., Senior Scientist, Merck 
•  Madhu Natarajan, Ph.D., Preclinical Therapeutic Area Head, Ophthalmology & Complement Biology, Shire 
•  Peter Neubauer, Ph.D., Professor, Department of Bioprocess Technology, Institute of Biotechnology, Technische Universität Berlin 
•  Juergen Nett, Ph.D., Director, High Throughput Expression, Adimab, LLC 
•  David Nicoli, Ph.D., Vice-President R&D, Particle Sizing Systems LLC
•  Dennis Niermeier, MSc, IBA Lifesciences 
•  Vaheh Oganesyan, MS, Scientist, MedImmune 
•  Teruyo Ojima-Kato, Ph.D., Researcher, Meijo University  
•  Adekunle O. Onadipe, Ph.D., Associate Research Fellow, Cell Line Development, Bioprocess R&D, Pfizer 
•  Marcin Paduch, Ph.D., Pipeline Director, Recombinant Antibody Network, University of Chicago 
•  Tadas Panavas, Ph.D., Senior Principal Scientist, Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals, Inc. 
•  Dimitris Papamichail, Ph.D., Assistant Professor, Computer Science, The College of New Jersey
•  Niv Papo, Ph.D., Group Leader and Assistant Professor, Biotechnology Engineering, Ben-Gurion University 
•  Diane Paskiet, MS, Director of Scientific Affairs, Scientific Affairs and Technical Services, West Pharmaceutical Services 
•  Edward F. Patz, Jr., M.D., Professor, Radiology, Pharmacology and Cancer Biology Duke University Medical Center 
•  Li Peng, Ph.D., Vice President, Antibody Engineering and Protein Sciences, Palleon Pharmaceuticals 
•  Robert Pejchal, Ph.D., Scientist, Antibody Engineering, Adimab LLC
•  Robert Peters, Ph.D., Senior Vice President, Research, Bioverativ, Inc. 
•  Mario Pereira, Ph.D., Senior Scientist, Horizon Discovery
•  Didier Pertuy, Vice President, Global Drug Device Integrated Development & Device Strategy, Sanofi, France 
•  Samuel Pollock, Researcher, Pharmaceutical Chemistry, University of California, San Francisco 
•  Dennis Powers, Director, Sales Engineering, G-CON Manufacturing 
•  James R. Prudent, Ph.D., President & CEO, Centrose LLC 
•  Enrico Purisima, Ph.D., Team Leader, Molecular Modeling, National Research Council Canada 
•  Laszlo Radvanyi, Ph.D., Senior Vice President, Senior Scientific Advisor, Immunology, Immuno-Oncology, EMD Serono R&D Institute (a business of Merck KGaA, Darmstadt, Germany) 
•  Czeslaw Radziejewski, Ph.D., Senior Principal Research Scientist, Biophysical Chemistry, AbbVie 
•  Smita Raghava, Ph.D., Senior Scientist, Sterile Formulation Sciences, Merck & Co.
•  G. Jonah Rainey, Ph.D., Executive Director, Research, MabVax Therapeutics Holdings, Inc. 
•  Alexey Rak, Ph.D., Head of Bio Structure and Biophysics, Integrated Drug Discovery, Sanofi R&D 
•  Srivatsan Raman, Ph.D., Assistant Professor, Departments of Biochemistry & Bacteriology, University of Wisconsin-Madison 
•  Servio Ramirez, Ph.D., Associate Professor, Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University 
•  Theodore W. Randolph, Ph.D., Kenneth and Genevieve Gillespie Professor, Department of Chemical and Biological Engineering, University of Colorado, Boulder 
•  Helen Rawsthorne, Ph.D., Senior Research Scientist, Molecular Biology and Fermentation, Albumedix 
•  Wayne F. Reed, Ph.D., Professor, Physics, Tulane University 
•  Christoph Reese, Ph.D., Director, Microbial Fermentation, Roche Diagnostics GmbH 
•  Dorothea Reilly, Ph.D., Principle Scientist and Associate Director, Early Stage Cell Culture, Genentech 
•  Nigel F. Reuel, Ph.D., Assistant Professor, Chemical and Biological Engineering, Iowa State University 
•  Joël Richard, Ph.D., Vice President, Peptides, CMC & Engineering, Ipsen 
•  Jerome Robert, PhD, Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia 
•  Gabriel Rocklin, Ph.D., Senior Fellow, Biochemistry & Bioengineering, University of Washington 
•  Miguel Ângelo Rodrigues, Ph.D., Researcher and Invited Professor, Chemical Engineering, Instituto Superior Técnico, University of Lisbon 
•  Floyd Romesberg, Ph.D., Professor, Chemistry, The Scripps Research Institute 
•  Enrique Miranda Rota, Ph.D., Research Associate, University College London Cancer Institute
•  Alice Rothnie, D.Phil., Lecturer, Biochemistry, Life & Health Sciences, Aston University 
•  David Rozzell, Ph.D., Senior Vice President, Biocatalysis, Provivi 
•  Kevin Rust, Ph.D., Principal Scientist, Bioprocess R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc. 
•  Natalie Saez, Ph.D., Senior Research Officer, Institute for Molecular Bioscience, The University of Queensland 
•  Miguel Saggu, Scientist, Late Stage Pharmaceutical Development, Genentech 
•  Andrey G. Sarafanov, Ph.D., Chemist, Principal Investigator, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA) 
•  Prasad Sarangapani, Ph.D., Staff Scientist, Protein Biochemistry, Regeneron Pharmaceuticals 
•  Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich 
•  Volker Schellenberger, Ph.D., President and CEO, Amunix 
•  Michael Schirm, Ph.D., Associate Director, R&D Proteomics, CAPRION BIOSCIENCES INC.
•  Tilman Schlothauer, Ph.D., Principal Scientist, Biochemical and Analytical Research, Large Molecule Research, Roche Innovation Center Munich 
•  Stefan Schmidt, Ph.D., MBA, CSO, Development and Innovation, Rentschler Biotechnology 
•  Christian Schoneich, Ph.D., Distinguished Professor and Chair, Pharmaceutical Chemistry, University of Kansas 
•  Lynette Schroeter, Crystalomics, Group Lead, Formulations Development, Althea CMO
•  Ian Schwartz, MS, CMC Expert, Antibody Drug Conjugate and Upstream/Downstream Process Development, Tech Transfer, and Manufacturing Ops, Sartorius Stedim Biotech 
•  Sebastian Schuck, Ph.D., Head, Business Development, Wacker Biotech GmbH 
•  Carolin Sellmann, Ph.D., Scientist, Protein Engineering and Antibody Technologies, Merck KGaA 
•  Saurabh Sen, Ph.D., Principal Scientist, Biotherapeutics Discovery, Boehringer Ingelheim 
•  Dinen Shah, Department of Pharmaceutical Sciences (Krishna Mallela Lab), University of Colorado Denver Health Sciences Center  
•  Justin Siegel, Ph.D., Assistant Professor, Biochemistry & Molecular Medicine, UC Davis Genome Center 
•  Michael Sierks, Ph.D., Professor, Chemical Engineering, Arizona State University 
•  Michael Siedler, Ph.D., Head, NBE High-Throughput and Advanced Formulation Sciences, Drug Product Development, AbbVie Deutschland GmbH & Co. KG 
•  Ian Shieh, Ph.D., Scientist, Genentech 
•  Judy Shimoni, Ph.D., Principal Scientist and Group Leader, Protein Analytical Chemistry, Genentech, Inc., a member of the Roche Group 
•  Nigel Shipston, Ph.D., Director of Program Design, FUJIFILM Diosynth Biotechnologies
•  Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata 
•  Eric Smith, Ph.D., Director, Bispecific Antibdies, Regeneron Pharmaceuticals, Inc. 
•  Chris Spahr, Senior Scientist, Therapeutic Discovery, Discovery Attribute Sciences, Amgen, Inc. 
•  Jason Stewart, BS, Senior Associate Scientist, Pharmaceutical Research and Development, Pfizer, Inc. 
•  Lars Stöckl, Ph.D., Director, Glycoprotein Development and PTM Analytics, Glycotope GmbH 
•  Kevin Strozyk, Sr. Research Associate, Analytical Sciences, Seattle Genetics 
•  Shanmuuga T. Sundaram, Ph.D., Research Advisor, BioAnalytical Sciences, Bioproduct Research and Development, Eli Lilly and Company 
•  David E. Szymkowski, Ph.D., Vice President, Cell Biology, Xencor, Inc. 
•  Saurabh Sen, Ph.D., Principal Scientist, Biotherapeutics Discovery, Boehringer Ingelheim 
•  Feng Shu, Ph.D., Senior Researcher, Chugai Pharmabody Research, Singapore 
•  Ken Skidmore, Technical Development Scientist, Protein Analytical Chemistry, Genentech 
•  Le Sun, PhD, CEO, AbMax Biotechnology
•  Michael Swanson, Ph.D., Senior Scientist, Merck 
•  Rastislav Tamaskovic, Ph.D., Senior Scientist, Biochemistry, University of Zurich 
•  Jamshid Tanha, Ph.D., Senior Research Officer, Human Health Therapeutics Portfolio, National Research Council Canada 
•  Hanna Tegel, Ph.D., Scientist and Group Leader, Biotechnology, Proteomics and Nanobiotechnology, KTH Royal Institute of Technology 
•  Devin Tesar, Ph.D., Scientist, Drug Delivery, Genentech 
•  Holger Thie, Ph.D., Associate Director, Molecular Biology, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG 
•  Jonas Hoeg Thygesen, Ph.D., Area Specialist, R&D - Microanalysis Centre, Novo Nordisk Pharmatech 
•  Elizabeth M. Topp, Ph.D., Dane O. Kildsig Chair and Department Head, Department of Industrial and Physical Pharmacy, Purdue University 
•  Riccardo Torosantucci, Ph.D., Head of Laboratory Formulation Development, Pharmaceutical Development Biologics, Sanofi-Aventis Deutschland GmbH 
•  Nicholas Turner, Ph.D., Professor, Chemical Biology, University of Manchester 
•  Thomas J. Van Blarcom, Ph.D., Associate Research Fellow, Rinat Laboratories, Oncology Research and Development, Pfizer, Inc. 
•  Ewald Van den Bremer, Ph.D., Senior Scientist, Genmab A/S 
•  Floris Van Delft, Ph.D., Founder & CSO, SynAffix BV 
•  James Van Deventer, Ph.D., Assistant Professor, Chemical and Biological Engineering, Tufts University 
•  Dmitry G. Vassylyev, Ph.D., Professor, Biochemistry and Molecular Genetics, University of Alabama at Birmingham 
•  Pandurangan Vijayanand, M.D., Ph.D., Associate Professor, Vaccine Discovery, La Jolla Institute for Allergy and Immunology 
•  Bjørn Voldborg, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark 
•  Moritz Von Stosch, Ph.D., Senior Manager, Fermentation, Technical R&D, GSK Vaccines 
•  Jonathan Wall, Ph.D., Professor and Director, Amyloidosis and Cancer Theranostics Program, University of Tennessee Medical Center 
•  Frank S. Walsh, Ph.D., CEO, Ossianix 
•  Tianyi Wang, Ph.D., Scientist, R&D, Sorrento Therapeutics 
•  E. Sally Ward, Ph.D., Professor, Molecular and Cellular Medicine, Texas A&M Health Science Center 
•  SiowFong Wee, Ph.D., Director, Formulation, Analytical & Bioassay, Aptevo Therapeutics 
•  Stefan Weigand, Ph.D., Head, Large Molecule Research, Roche Innovation Center, Roche Pharma 
•  Andrew Weinberg, Ph.D., Judy Ann Hartmann Endowed Chair for Cancer Immunology Research, Robert W. Franz Cancer Research Center 
•  David Weiner, Ph.D., Vice President, Technology & Product Development, BASF Enzymes, LLC 
•  Mark Welch, Ph.D., Vice President, Research and Development, ATUM (formerly DNA2.0) 
•  James A. Wells, Ph.D., Professor, Pharmaceutical Chemistry, University of California, San Francisco 
•  Tim Wenzel, Scientist, Ph.D. Candidate, University of Erlangen GILYOS GmbH 
•  David Wood, Ph.D., Professor, Professor, Chemical & Biomolecular Engineering, The Ohio State University
•  Dongxin Zhao, Ph.D., Postdoctoral Fellow, Prashant Mali Lab, Department of Bioengineering, University of California, San Diego 
•  Gregory A. Weiss, Ph.D., Professor, Chemistry and Molecular Biology & Biochemistry, University of California, Irvine 
•  Helen Wu, Ph.D., Senior Scientist, Boehringer Ingelheim Pharmaceuticals Inc
•  Jiansheng Wu, Ph.D., Principle Scientific Manager, Protein Chemistry, Genentech, Inc. 
•  Zhen Wu, Ph.D., Senior Scientist, AbbVie 
•  Mingjie Xie, MSc, MBA, CEO, Rapid Novor Inc
• Yemin Xu, Ph.D., Senior Regulatory Scientist, Regulatory Science, Regeneron
•  Noriko Yamano, Ph.D., Senior Scientist, Manufacturing Technology Association of Biologics; Guest Academic Staff, Graduate School of Engineering, Osaka University 
•  Danlin Yang, Ph.D., Scientist, Biophysics, Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals 
•  Alexei Yeliseev, Ph.D., Staff Scientist, LMBB, NIH/ NIAAA 
•  Mimi Cho Yung, Ph.D., Biomedical Staff Scientist, Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory 
•  Alexandre Zanghellini, Ph.D., CEO, Arzeda 
•  Qingchun Zhang, Ph.D., Senior Scientist, Amgen, Inc. 
•  Wei Zhang, Ph.D., Mitacs Elevate Fellow, University of Toronto, Canada 
•  Ali Zarrin, Ph.D., Senior Scientist, Immunology and Antibody Engineering, Genentech 
•  Zhongqi Zhang, Ph.D., Scientific Director, Attribute Sciences, Process Development, Amgen 
•  Huiman Zhao, Ph.D., Departments of Chemical and Biomolecular Engineering, Chemistry, and Biochemistry, Bioengineering, Institute for Genomic Biology, and Center for Biophysics and Computational Biology, University of  Illinois 
•  Haihong (Helen) Zhong, Ph.D., Senior Scientist, Oncology Research, MedImmune, Inc. 
•  Qi (Tony) Zhou, Ph.D., Assistant Professor, Industrial and Physical Pharmacy, Purdue University 
•  Kyle Zingaro, Ph.D., Development Scientist II, Early Stage Development, Alexion Pharmaceuticals 
•  Jonathan Zmuda, Ph.D., Director, Cell Biology R&D, Thermo Fisher Scientific
•  Zhongcheng Zou, Ph.D., Staff Scientist, Structural Immunology Section, Lab of Immunogenetics, NIAID/NIH